Blog
RSS FeedPosted by Michael Wonder on 10 Dec 2024
PHARMAC seeks feedback to fund medicines for liver and ovarian cancer
9 December 2024 - PHARMAC is consulting on a proposal to fund bevacizumab (branded as Vegzelma) as a cancer medicine ...
Posted by Michael Wonder on 16 Nov 2021
PHARMAC widens access to adalimumab through transition to biosimilar
17 November 2021 - Pharmac’s chief medical officer Dr David Hughes has today announced the decision to fund a biosimilar adalimumab ...
Posted by Michael Wonder on 26 Aug 2021
PHARMAC seeks feedback on a biosimilar brand of adalimumab being considered for funding
26 August 2021 - PHARMAC is considering awarding Principal Supply to a biosimilar brand of adalimumab (Amgevita) from 1 February ...
Posted by Michael Wonder on 09 Mar 2021
Request for proposals - supply of adalimumab
9 March 2021 - PHARMAC invites proposals for the supply of adalimumab in New Zealand. ...
Posted by Michael Wonder on 21 May 2020
Proposal to award sole supply of infliximab in DHB hospitals
21 May 2020 - PHARMAC is proposing to award sole supply of infliximab, a biologic medicine used to treat a ...
Posted by Michael Wonder on 06 Jun 2019
Decision to widen access to etanercept and award sole supply
6 June 2019 - PHARMAC has made a decision to make changes to the funding of etanercept, a biologic medicine ...
Posted by Michael Wonder on 05 Nov 2018
RFP - supply of etanercept
5 November 2018 - PHARMAC invites proposals for the supply of etanercept in New Zealand. ...
Posted by Michael Wonder on 25 Sep 2018
Decision to change the funded brand of epoetin alfa
24 September 2018 - PHARMAC is pleased to announce the approval of an agreement with Novartis for the supply of ...
Posted by Michael Wonder on 21 Aug 2018
Proposal to change the funded brand of epoetin alfa
21 August 2018 - PHARMAC is seeking feedback on a proposed change to the funded brand of epoetin alfa [erythropoietin ...